Introduction
Introduction
Since the discovery of prostacyclin (PGI2) in 1976, there has been great interest in its vascular effects and potential clinical applications. High infusion rates of PGI2 markedly depress arterial blood pressure both in animal studies and in clinical trials. This fall in pressure may result entirely from a decrease in arterial resistance. However, it is possible that the administration of PGI2 may decrease ventricular filling due to an increase in vascular capacity. To investigate whether or not PGI2 affects vascular capacity, we infused PGI2 intraarterially at both 10 and 25 gg/min into 15 dogs on total cardiopulmonary bypass. These infusions were associated with a 25±3 mmHg decrease in arterial pressure and an increase in vascular capacity of 155±29 ml (SE, P < 0.005). This increase in capacity was greater (P < 0.02) than the increase of 23±42 ml resulting from infusions of nitroglycerin into eight dogs at 2 mg/min, which produced a decrease in arterial pressure of 23±4 mmHg, which was the maximal effect that could be achieved. Neither bilateral cervical vagotomy nor beta adrenergic blockade with propranolol significantly diminished the increase in vascular capacity associated with infusions of PGI2. The results from studies in four eviscerated dogs indicated that PGI2 acts on both splanchnic and extrasplanchnic capacity vasculature.
To compare the direct effects of PGI2 with those of nitroglycerin and nitroprusside on venous tone, we used an isolated canine spleen preparation. Infusions of PGI2 (100 mcg/min) increased spleen weight in this preparation by 9.0±2.4% (n = 10, P < 0.001); this increase was significantly greater than increases of 3.6±2.2% (P < 0.001) and 3.5±2.3% (P < 0.001) caused by high dose infusions of nitroglycerin (1 mg/min) and nitroprusside (400 jig/min), respectively. Thus, PGI2 substantially increases vascular capacity by a mechanism that appears to involve a direct action on vascular smooth muscle. Furthermore, these results suggest that PGI2 might be useful in clinical conditions in which an increase in vascular capacity is indicated.
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Receivedfor publication 16 March 1984 and in revisedform 3 May 1985. Since the discovery of prostacyclin (PGI2)' (epoprostenol) by Bunting et al. (1) and Moncada and Vane (2) in 1976, a variety of effects of this agent on the cardiovascular system have been described (1, 2) . The finding that PGI2 is the most potent known endogenous inhibitor ofplatelet aggregation suggests its possible use in reducing the deposition ofplatelets and fibrin on the filter mesh in patients undergoing operations with cardiopulmonary bypass (3) (4) (5) (6) . As an antiplatelet agent, PGI2 can successfully replace heparin as the sole antithrombic agent in patients with renal failure undergoing hemodialysis (7, 8) . Its administration is associated with neither anticoagulation nor hemorrhage (7) . However, in the latter study, symptomatic hypotension occurred in all cases, and in two patients necessitated termination of dialysis because of precipitous decreases in blood pressure.
With regard to the hemodynamic effects of PGI2, it has been established that this agent relaxes most in vitro vascular preparations, including rabbit mesenteric arteries, bovine coronary arteries, and human cerebral arteries (1, 9, 10), and reduces systemic vascular resistance. This vasodilating action has therapeutic potential. For example, beneficial effects of PGI2 have been demonstrated in patients with pulmonary hypertension (11) (12) (13) (14) , peripheral ischemic vascular disease (15) (16) (17) (18) (19) , and unstable angina (20) . Furthermore, the increase in tissue conductance, which is the reciprocal ofvascular resistance, particularly in the splanchnic circulation, coupled with the augmentation of cardiac output, which has been established experimentally, provides rationale for the use of PGI2 in the management of congestive heart failure (21). Yui and coworkers (22) have recently demonstrated that the infusion of PGI2 in nine patients with severe congestive heart failure resulted in a significant decrease in mean aortic pressure, systemic vascular resistance and pulmonary capillary wedge pressure, and a significant and substantial increase in cardiac output.
Thus, PGI2 has a potential role during the use of extracorporeal circulation but produces hypotension. Its vasodilator properties, on the other hand, give it potential in the treatment ofconditions of decreased arterial perfusion and in the treatment of congestive heart failure. Studies to date have focused on the arterial circulation, and little is known about the effects of PGI2 on systemic vascular capacity. This latter effect may contribute to the overall hemodynamic effects produced by the administration ofthis agent. Vascular capacity determines venous return, ventricular filling and, thus, cardiac performance. Therefore, the present study was carried out to determine whether PGI2 alters vascular capacity, to localize the changes observed, and to compare the effects of PGI2 on vascular capacity with those of nitroglycerin, a commonly used venodilating agent.
Methods 68 mongrel dogs weighing between 17 and 25 kg were anesthetized with chloralose (60 mg/kg i.v.) and urethane (600 mg/kg i.v.). The animals were ventilated with a Bird Mark 7 constant pressure respirator (Bird Corp., Palm Springs, CA) using 97% 02 and 3% Co2. A right lateral thoracotomy was performed and a total cardiopulmonary bypass preparation, which has previously been used in our laboratory to study vascular capacity (23, 24) , was used (Fig. 1) . After heparin administration ( (23, 24) . Computer-assisted regression lines were drawn through the control period and the lines were extrapolated for oxygenator blood volume throughout the study as previously described (24) . Changes produced by an intervention were measured as the differences between the extrapolated regression line and the observed oxygenator volumes.
The justification of this extrapolation was verified in 10 additional experiments, all with 11 distinct, equally spaced sample points in a 10-min control period. Straight lines were fit to the control period points and variances in the estimated regression lines were computed for each minute post control out to the full 20-min experimental protocol. The standard estimates for variance in the prediction ofa population regression line were employed (25) . These minute by minute variance estimates, which result in hyperbolic confidence belts around the straight line which is extrapolated from the control period into the experimental period, were then pooled across all 10 experiments at each minute using the standard method for pooling variance estimates from independent sources (26) . The (27) . Individual data points also were tested for significance using a double-tailed, paired t test, as were data obtained from the isolated spleen preparations. Significance was assumed only if P < 0.05.
Results
Six dogs on total cardiopulmonary bypass received infusions of PGI2 at 10 mcg/min, and 9 dogs received infusions at 25 mcg/ min. The mean increases in vascular capacity at 10 min of infusion for the 10-and 25-,gg infusions were 162±52 and 150±34 ml (mean±SE), respectively (Fig. 2) . The corresponding decreases in arterial pressure at 10 min were 25±7 and 25±2 mmHg. These results confirmed preliminary experiments indicating that these delivery rates produced maximal effects on both vascular capacity and arterial pressure; therefore, results of the 15 experiments were grouped together for further analyses. Fig. 4 . Capacity began to increase at the initiation of the infusion, and reached a mean increase of 155±29 ml (P < 0.005) at the end of the 10-min infusion.
Four animals were eviscerated to investigate whether the entire increase in vascular capacity occurred in either the splanchnic or peripheral capacity vasculature. At the end of a 10-min infusion of PGI2, vascular capacity increased by 74±27 ml (P < 0.001), which was significantly different (P < 0.02) from the mean increase of 155 ml in the group not eviscerated (Fig.  5) . Four dogs were splenectomized to be certain that the canine spleen, which has a muscular capsule, did not account for the entire increase in vascular capacity. Fig. 5 compares the mean increase in capacity in the splenectomized animals with the mean increase of the group that was not splenectomized. The mean increase in the four splenectomized dogs was 210±65 ml; this gain did not differ significantly from the mean increase in the intact group.
Five infusions were performed in three animals after bilateral cervical vagotomy, with two of the animals receiving second infusions. The middle panel ofFig. 4 shows that vascular capacity increased 195±47 ml by the end of the infusions, compared with an increase of 155±29 ml in the animals that were not vagotomized (NS). Five dogs received infusions after beta adrenergic blockade. As illustrated in the bottom panel of Fig. 4 , the mean increase at the end ofthe infusion in the beta adrenergic blocked group was 89±72 ml; this change did not differ significantly from that in the unblocked group. One beta adrenergic blocked dog did not increase its capacity during the PGI2 infusion, and thus lowered the group mean. The other four beta adrenergic-blocked dogs, however, increased capacity by a mean of 159 ml; this increase was nearly identical to the increase of 155 ml in the unblocked group. Nitroglycerin was infused at 2 mg/min, a dose which we determined produced maximal effects on arterial pressure and vascular capacity, in eight dogs on total cardiopulmonary bypass. We isolated and perfused 10 spleens to compare the vasodilating action of PGI2 with that of nitroglycerin and nitroprusside. When PGI2 was infused at 100 mcg/min for 5 min, spleen weight increased by 9.0±2.4% (P < 0.001). Infusions of nitroglycerin at 1 mg/min increased spleen weight by 3.6±2.2% (P < 0.001), and nitroprusside infused at 400 mcg/min increased spleen weight by 3.5±2.3% (P < 0.001). The mean increase in weight during infusions with PGI2 was significantly greater than were the mean increases during infusions ofeither nitroglycerin or nitroprusside (P < 0.001).
Discussion
Infusion of prostacyclin is associated with a marked increase in total intravascular capacity. This increase occurs in both the splanchnic and extrasplanchnic capacity vasculature and appears secondary to an effect of PGI2 on vascular smooth muscle. Furthermore, in the canine models studied, PGI2 increases vascular capacity significantly more than nitroglycerin, which has, to date, been considered one of the most potent venodilating agents available (28, 29) .
With regard to the site ofaction ofPGI2 in increasing vascular capacity, recent studies have demonstrated that one mechanism of altering vascular capacity in the dog is through increased or decreased transhepatic vascular resistance, with resultant changes in splanchnic vascular capacity (28, 29). Acetylcholine, for example, increases transhepatic resistance to blood flow resulting in portal venous pooling (29) , whereas isoproterenol decreases transhepatic resistance, allowing blood from the portal venous circulation to enter the central circulation (28 Figure 5 . Comparison of the effect of intra-arterial infusions of prostacyclin on vascular capacity in the 15 intact animals to that of four animals that were eviscerated and to that of four animals that were splenectomized. Removal of the splanchnic organs significantly reduced (P < 0.02), but did not eliminate, the increase in capacity. Splenectomy alone did not significantly change the increase in capacity due to PGI2. Increases in vascular capacity were significantly above control capacity in each group (P < 0.001).
certain areas of the venous system (32) (33) (34) . This raised the possibility that PGI2 increases vascular capacity through beta adrenergic stimulation ofsome areas ofthe capacitance vasculature.
To investigate this possibility, we infused PGI2 after beta adrenergic blockade. The mean increase in vascular capacity in these experiments did not differ significantly from that in the control preparations, which indicated that PGI2 increases vascular capacity by a mechanism other than beta adrenergic receptor Thus, PGI2 may not relax some in vitro preparations of large veins, but it is a potent dilator ofoverall capacitance vasculature in the dog.
The dose of PGI2 that has been employed in canine studies has been substantially higher than that used in clinical studies. For example, in a study on coronary artery patency in the dog (40) and in a study on nutrient perfusion in the canine brain (41) , the dosages ofPGI2 employed were 20-25 times those used by Zusman and coworkers (7, 8) in their investigation of the antiplatelet effect of PGI2 in patients undergoing hemodialysis. The maximum dosage employed by Zusman (8) was 8 ng/kg per min. It is of interest that in the clinical study of the effects of PGI2 on congestive heart failure by Yui and coworkers (22) , a mean dose of 22 ng/kg per min was necessary to produce decreases in mean arterial pressure of 23 mmHg. In the present study, the infusion rate of PGI2 of 10 mcg/min produced approximately the same decrease in mean arterial pressure as this latter clinical study. This rate ofdelivery, not taking into account hemodilution by blood from two donor dogs in the extracorporeal circuit, is -22 times that employed by Yui (22) . If, for the same decrease in blood pressure, the findings in dogs are representative of those in man, similar changes in venous capacity should occur in the human. However, the exact magnitude of the changes in venous capacity in the human with PGI2 remains to be determined, and caution must be exercised in comparing effects across species due to the differences in dosages needed to demonstrate similar arterial effects. PGI2 and nitroglycerin produced markedly different effects on both the magnitude and time-course of action of changes in vascular capacity. Vascular capacity increased for the entire period of PGI2 infusion, and then returned toward the control level of capacity. While PGI2 has been implicated as a mediator for certain actions of nitroglycerin on vascular preparations (42) (43) (44) , the disparity of action of nitroglycerin and PGI2 on both the magnitude and time course of change in vascular capacity suggests that nitroglycerin may change vascular capacity in the present study by a mechanism other than through the release of endogenous PGI2. This finding is consistent with the recent work by Bennett et al. (45) , which demonstrated that nitroglycerin-induced relaxation of isolated rabbit celiac and mesenteric arterial rings appears to be mediated through a mechanism other than stimulation of PGI2 synthesis. It is known that coronary arteries develop tolerance to the vasodilating action of nitroglycerin (46), and that patients who have previously received isosorbide dinitrate develop a cross-tolerance to nitroglycerin (47) . The greater the effect of PGI2 on vascular capacity, as well as the lack of a demonstration of tolerance development to PGI2, suggests the feasibility of clinical investigation in man to compare the effects on vascular capacity of PGI2 and nitroglycerin.
The action of PGI2 on vascular capacity has several important clinical implications. First, additional volume may be required to maintain hemodynamic stability in patients receiving PGI2, such as those on hemodialysis (7, 8) or in whom extracorporeal membrane oxygenation is employed (4-6). Second, PGI2 may be valuable in conditions in which an increase in vascular capacity is desired, as in the treatment of severe congestive heart failure that is refractory to conventional therapy (22) . A substantial part of this salutory effect may be due to a reduction in preload that is secondary to an increase in intravascular capacity rather than solely secondary to a reduction of systemic vascular resistance. Prostacyclin may not only be safe to use in patients with severe congestive failure due to ischemic heart disease, but may actually exert a protective effect on ischemic myocardium. Bergman and coworkers (48) have shown that intravenous PGI2 increases mean atrial pacing time to clinical angina and increases the lactate extraction ratio. Not only, as shown in the present study, may PGI2 protect ischemic myocardium by decreasing venous return, ventricular wall tension, and thus myocardial oxygen consumption, but, as shown by Lefer et al. (49) , PGI2 administered intravenously decreases the mean arterial pressure, and hence the tension time index, without increasing heart rate. Dusting and coworkers (50) and Einzig and coworkers (5 1) have both shown that PGI2 induces coronary vasodilatation in anesthetized dogs. PGI2 may also preserve ischemic myocardium by preventing the adhesion and aggregation of platelets in atherosclerotic coronary arteries. Furthermore, Araki and Lefer (52) have demonstrated that PGI2 has a direct cytoprotective effect in ischemic myocardium which is independent of its inhibitory effect on platelet aggregation, its effect on lowering systemic blood pressure, and its effect on producing coronary vasodilatation (52) . Thus, the present finding that PGI2 has the potential of reducing preload may find wide clinical application.
